Navigation Links
Zyngenia, Inc. Promotes Chief Scientific Officer and Hires Chief Business Officer
Date:12/12/2011

ion. Before joining Merck KgaA, Mr. Menichella was President of MorphoSys USA and Senior Vice President of MorphoSys AG, a German therapeutic antibody company, with primary responsibility for worldwide business development and management of the U.S. business unit. Mr. Menichella earned his B.A. from Harvard University and his M.B.A. from the University of North Carolina at Chapel Hill.

About Zyngenia, Inc.

Founded in 2008, Zyngenia, Inc. is a privately held biotherapeutics company focused on the development of next-generation multi-specific antibody-based therapeutics. The company uses proprietary patented technology to engineer single molecular entities that interact with two or more targets. The multiple target strategy has created many opportunities for innovative therapeutics with new mechanisms of action that are not achievable with single specificity antibodies. The company has initially focused its Zybody™ development on therapies for various cancers and autoimmune disorders. Zyngenia is headquartered in Gaithersburg, Maryland. For more information, visit www.zyngenia.com.

 


'/>"/>
SOURCE Zyngenia, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Zyngenia, Inc. Raises $10 Million in Series A Funding
2. China Bionanometer Industries Corporation Promotes New Product Beauty Look in China
3. WuXi PharmaTech Promotes Dr. Rujian Ma to VP of Synthetic Chemistry
4. AMDL, Inc. Promotes CFO Akio Ariura to Chief Operating Officer and Expands Management Team
5. BioMed Realty Trust Promotes Kent Griffin to President
6. Genesis HealthCare Promotes Wendy LaBate To Senior Vice President of Operations for the Northeast Area
7. BioStorage Technologies, Inc. Promotes Lori Ball to Senior Vice President and Expands Role
8. Merrimack Pharmaceuticals Promotes Ulrik B. Nielsen, Ph.D. to Chief Scientific Officer and Edward J. Stewart to Senior Vice President of Business Development
9. Pathway for Biosimilars Act Protects Patients, Promotes Competition, Preserves Innovation and Creates Quality Jobs, Lilly Says
10. Ratcliff Promotes Jorge Burbano to Senior Associate; Tess Kavanagh and Tony Keung to Associate
11. Nektar Therapeutics Promotes Lorianne Masuoka, M.D. to Chief Medical Officer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/3/2015)... /PRNewswire/ - Aptose Biosciences Inc. (NASDAQ: APTO, TSX: APS), ... that target the underlying mechanisms of cancer, today reported ... December 31, 2014. Effective July 17, 2014, ... 31 to December 31. As a result of that ... the quarter and the seven months ended December 31, ...
(Date:3/3/2015)... March 03, 2015 Experts and industry ... for one event: the Alltech REBELation exploring innovation, inspiration ... 17-20. Now in its 31st year, Alltech’s annual international ... countries, and the opportunity to join the REBELation at ... at 11:59 p.m. EST, at which point the standard ...
(Date:3/3/2015)... , March 3, 2015  Neurocrine Biosciences, Inc. (Nasdaq: ... Gorman , President and Chief Executive Officer of Neurocrine ... Conference in Miami.   The live presentation ... (7:15am PT).  The presentation will be webcast and may ... .   Listeners are encouraged to visit ...
(Date:3/3/2015)... BlueInGreen announces the addition ... network. The business venture will bring the world’s ... Provinces, exclusively through Resource Systems. , Since 1986, ... premiere manufacturing representative firms, hosting a diverse portfolio ... wastewater markets. More information on Resource Systems is ...
Breaking Biology Technology:Aptose Biosciences reports results for the quarter and seven months ended December 31, 2014 2Aptose Biosciences reports results for the quarter and seven months ended December 31, 2014 3Aptose Biosciences reports results for the quarter and seven months ended December 31, 2014 4Aptose Biosciences reports results for the quarter and seven months ended December 31, 2014 5Aptose Biosciences reports results for the quarter and seven months ended December 31, 2014 6Aptose Biosciences reports results for the quarter and seven months ended December 31, 2014 7Aptose Biosciences reports results for the quarter and seven months ended December 31, 2014 8Aptose Biosciences reports results for the quarter and seven months ended December 31, 2014 9Aptose Biosciences reports results for the quarter and seven months ended December 31, 2014 10Aptose Biosciences reports results for the quarter and seven months ended December 31, 2014 11Aptose Biosciences reports results for the quarter and seven months ended December 31, 2014 12World-renowned Leaders, Authors and Businesspeople Join the Alltech REBELation 2World-renowned Leaders, Authors and Businesspeople Join the Alltech REBELation 3World-renowned Leaders, Authors and Businesspeople Join the Alltech REBELation 4BlueInGreen® Continues Canadian Expansion, Partners with Resource Systems Inc. 2
... in Second Pivotal Clinical Trial , WASHINGTON, Nov. ... today announced positive results from BLISS-76, the second of ... for treating systemic lupus. A full presentation of ... Annual Scientific meeting of the American College of Rheumatology. ...
... powder from her ring into wine glasses carelessly left unattended. ... holding a cabochon or faceted gemstone that can be broken ... so large it is rather odd nobody seems to notice ... the "smart capsule" devised in Younan Xia,s laboratory at ...
... DIEGO and INDIANAPOLIS, Oct. 30, 2009 Amylin Pharmaceuticals, Inc., ... LLY ) today announced that the U.S. Food and ... (exenatide) injection. BYETTA is now approved for use as a ... glycemic control in adults with type 2 diabetes. Previously, it ...
Cached Biology Technology:Promise of a New Lupus Treatment Is a Groundbreaking Achievement 2Promise of a New Lupus Treatment Is a Groundbreaking Achievement 3An exquisite container 2An exquisite container 3An exquisite container 4An exquisite container 5BYETTA Approved for Expanded Use as First-Line Treatment for Type 2 Diabetes 2BYETTA Approved for Expanded Use as First-Line Treatment for Type 2 Diabetes 3BYETTA Approved for Expanded Use as First-Line Treatment for Type 2 Diabetes 4BYETTA Approved for Expanded Use as First-Line Treatment for Type 2 Diabetes 5BYETTA Approved for Expanded Use as First-Line Treatment for Type 2 Diabetes 6BYETTA Approved for Expanded Use as First-Line Treatment for Type 2 Diabetes 7
(Date:2/12/2015)... 2015   MedNet Solutions , a global ... management systems, has recently bolstered its ... iMedNet as the eClinical solution ... healthcare consultants.  Building on the Program,s existing benefits ... numerous co-marketing opportunities), MedNet,s new and improved program ...
(Date:2/5/2015)... Carolina , 5. Februar 2015 /PRNewswire/ ... als spezialisiertes Logistikunternehmen und hat eine neue ... klinische Logistikfirma (Clinical Logistics Organization – CLO) ... neuen Kampagne lautet First , mit ... Foto: http://photos.prnewswire.com/prnh/20150205/173753 ...
(Date:2/5/2015)... , January 28, 2015 ... Analysis, Size And Segment Forecasts To 2020 has Been ... IR camera market is expected to reach USD 5.10 ... Grand View Research, Inc. IR cameras help identify the ... are expected to witness surging demand in medical imaging ...
Breaking Biology News(10 mins):MedNet Solutions Announces Key Enhancements To Its iMedNet Partner Program 2Marken startet Kampagne mit Patienten im Mittelpunkt 2Marken startet Kampagne mit Patienten im Mittelpunkt 3IR Camera Market Worth $5.10 Billion By 2020: Grand View Research, Inc. 2IR Camera Market Worth $5.10 Billion By 2020: Grand View Research, Inc. 3
... new University of Colorado at Boulder study shows the ... populations, findings with implications for the fate of ecological ... also is the first to indicate that at least ... quiet ones, perhaps because of their vocalization pitches, a ...
... The U.S. Environmental Protection Agency has awarded a ... how allergic reactions to food are initiated. The research ... whether pesticides produced in genetically engineered plants can trigger ... each year. The study is funded through EPA,s Science ...
... Utah researchers and their colleagues have identified the gene that ... tumor called paraganglioma (PGL). The gene, called hSDH5, is required ... role in the chemical reactions that take place within cells ... be published in the journal Science , to be ...
Cached Biology News:Noise pollution negatively affects woodland bird communities, says CU-Boulder study 2Noise pollution negatively affects woodland bird communities, says CU-Boulder study 3Scientists discover gene mutation responsible for hereditary neuroendocrine tumor 2Scientists discover gene mutation responsible for hereditary neuroendocrine tumor 3
... An entire pressurized perfusion system ... in physiology, biophysics, electrochemistry, or general ... as little as 100 microliters of ... eight solutions in milliseconds from a ...
Anti-Digoxigenin-AP, Fab fragments; from sheep...
...
... Immunogen: Partially purified ... MA1-710 detects vitamin D receptor (VDR) ... amphibian, and fish tissues. This ... or glucocorticoid receptors. MA1-710 detects ...
Biology Products: